To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138 + tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8 + CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA 72-80 (YLMFLLRKI), and BCMA 54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA 72-80 specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-γ/IL-2/TNF-α production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer + and memory CD8 + CTL. Additionally, heteroclitic BCMA 72-80 specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA 72-80 peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.
Introduction
Despite recent advances in treatment of multiple myeloma (MM) including incorporation of novel therapies into the stem cell transplantation paradigm, ongoing DNA damage and genomic evolution underlie relapse in many patients [1, 2] . Novel therapeutic approaches with distinct mechanisms of action are therefore needed. The constitutive evolving genetic complexity, coupled with immune responsiveness of B-cell malignancies, has stimulated the development of immunotherapeutic options in MM including monoclonal antibodies, bispecific antibodies, immunotoxins, and chimeric antigen receptor T cell (CAR-T) [3, 4] . Although MM patientspecific CAR-T therapy has achieved remarkable deep responses, durability of responses is not establishes and they are labor-intensive, time-consuming, and expensive [5] [6] [7] [8] . To overcome these limitations, we have developed immunogenic peptides-based cancer vaccines as an off-the-shelf immunotherapy for treating patients more widely and efficiently [9, 10] . Our peptide-based therapeutic approach does not have limitations of recombinant proteins, mRNA, or DNA-based vaccines, which require the processes of internalization, degradation of protein into optimal immunogenic peptides to HLA, along with additional steps required for suitable translation (for mRNA) or transcription (for DNA). To overcome MHC restriction and treat a more diverse patient population using our well-defined immunogenic peptide vaccine approach, we have pooled peptide cocktails to include major HLA subtypes [11] [12] [13] . Moreover, we have already shown that lenalidomide can augment peptide vaccine-specific immune responses and memory cytotoxic T cell (CTL) activities, setting the stage for combination approaches with checkpoint inhibitors and/or immune agonists. In addition, anti-tumor efficacy triggered by immunogenic peptides can be enhanced by their ability to induce "epitope spreading" upon the generation of effector cells, whereby targeted lysed cancer cells release new antigenic epitopes which are subsequently taken up, processed, and presented by antigen-presenting cells to a new repertoire of CTLs [14, 15] .
B-cell maturation antigen (BCMA) is a member of the TNF receptor superfamily 17 (TNFRSF17) and is characterized as a type III trans-membrane protein containing cysteine-rich extracellular domains with a central role in regulating B-cell maturation and differentiation into plasma cells [16] [17] [18] . As a receptor for the MM cell growth and survival factors, B-cell activating factor (BAFF) and a proliferationinducing ligand (APRIL), BCMA is required for the survival of MM cells, making it a promising therapeutic target [19, 20] . Nearly all MM tumor cells express BCMA, and it has been proposed as a marker for identification of tumor cells [21] [22] [23] [24] [25] [26] . Its selective expression on a subset of mature B and long lived plasma cells further suggest a favorable therapeutic index for BCMA directed treatment approaches. At present BCMA is being targeted by several immunotherapeutic strategies including antibodies (naked antibodies, antibodies-drug conjugates, and bispecific antibodies) and cellular therapies (chimeric antigen receptor T cells), with promising clinical results even in relapsed refractory MM [23, [27] [28] [29] [30] . In addition, serum soluble BCMA is elevated among patients with MM and chronic lymphocytic leukemia and can served as a prognostic marker and monitor of clinical response. Finally, most recent studies indicate that BCMA is expressed in non-hematopoietic tissue: BCMA is abnormally expressed in non-small cell lung cancer cell lines and may play a role in the tumors through the ERK1/2 signaling pathway [31, 32] . These data support targeting BCMA in immunotherapeutic strategies in MM and potentially BCMA expressing solid tumors as well.
In the present study, we developed a peptide-based immunotherapeutic approach targeting BCMA that induces development of antigen-specific CD8 + CTL with effective and long-lasting immunity against MM cells. 
Materials and methods

Cell lines
The [54] [55] [56] [57] [58] [59] [60] [61] [62] (YILWTCLGL), and hBCMA 9-17 (YQNEYFDSL)] and HIV-Gag 77-85 (SLYNTVATL) were synthesized by standard fmoc (9-fluorenylmethyl-oxycarbonyl) chemistry, purified to > 95% using reverse-phase chromatography, and validated by mass-spectrometry for molecular weight (Biosynthesis, Lewisville, TX).
HLA-A2 affinity and stability assays T2 cells were pulsed overnight with various doses of peptide plus β2-microglobulin (3 µg/ml) (Sigma, St Louis, MO). Following overnight incubation, the cells were stained with HLA-A2-PE mAb and analyzed by flow cytometry. Peptide/ HLA-A2 complex stability was measured on peptide loaded T2 cells at 0, 2, 4, 6, and 14 h post-Brefeldin A treatment by staining with HLA-A2-PE mAb and flow cytometry analyses and shown as an increase in specific HLA-A2 median fluorescence intensity (MFI).
Generation of dendritic cells (DC)
Peripheral blood mononuclear cells (PBMC) were isolated by standard density gradient centrifugation over FicollPaque TM Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden) from leukopaks obtained from multiple HLA-A2 + normal donors. Monocytes isolated from the PBMC were cultured for 7 days in the presence of 1000 units/ml GM-CSF and 1000 units/ml IL-4 in RPMI-1640 medium (Gibco-Life Technologies) supplemented with 10% FCS. Fresh media plus GM-CSF and IL-4 was added to the cultures every other day. Mature DC (mDC) were obtained on day 7, following three additional days incubation with 1000 units/ml IFN-α plus 10 ng/ml TNF-α.
Induction of heteroclitic BCMA peptide-specific CTL 
Statistical analysis
Summary results are presented as the mean ± SE. Groups were compared using unpaired Student's t-test. Differences were considered significant when *p < 0.05.
Results
Heteroclitic BCMA 72-80 peptide shows the highest affinity and stability to HLA-A2 molecules
The full length BCMA protein sequence was evaluated to predict epitopes with HLA-A2 affinity, extended half-time disassociation rates, proteasome C terminal cleavage, and TAP transport using various search software programs. Among the six native peptides selected [BCMA [64] [65] [66] [67] [68] [69] [70] [71] [72] (LIISLAVFV), BCMA 69-77 (AVFVLMFLL), BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] (AILWTCLGL) showed the highest HLA-A2 binding affinity in a dose-dependent manner, indicated as a significant increase in HLA-A2-specific MFI from baseline (n = 3, *p < 0.05) (Fig. 1a) . Furthermore, the native BCMA 72-80 (VLMFLLRKI) and BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] (AILWTCLGL) peptides with highest HLA-A2 binding affinity were chosen for modification of their anchor residues to further enhance HLA-A2 affinity. The HLA-A2 non-specific BCMA 9-17 (SQNEYFDSL) peptide was also modified to evaluate whether a change in an anchor motif alters HLA-A2 affinity. Among the engineered peptides designed, heteroclitic BCMA 72-80 (YLMFLLRKI) and heteroclitic BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] (YILWTCLGL) peptides displayed a significant increase in HLA-A2 affinity than their native peptides (n = 3, *p < 0.05). The highest affinity was detected by heteroclitic BCMA 72-80 (YLMFLLRKI) in both doses (50 μg/ml, 100 μg/ml) tested, which was close to the binding affinity of the HLA-A2-specific HIV-Gag 77-85 (SLYNTVATL) peptide (n = 3, *p < 0.05) (Fig. 1b) .
In contrast, replacing the anchor motif in the non-HLA-A2 specific BCMA 9-17 (SQNEYFDSL) to heteroclite BCMA 9-17 (YQNEYFDSL) did not alter its HLA-A2 affinity status, indicating that improved HLA-A2 affinity is only achieved in HLA-A2-specific peptides. In addition, native BCMA 72-80 and BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] peptides displayed extended HLA-A2 stability for >6 h, which was further enhanced in the engineered heteroclitic BCMA 72-80 (YLMFLLRKI) and BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] (YILWTCLGL) peptides, close to the stability of the HLA-A2-specific HIV-Gag 77-85 peptide (n = 3, *p < 0.05) (Fig. 1c) . In summary, the heteroclitic BCMA 72-80 peptide had the highest level of HLA-A2 affinity and stability, which was close to the HLA-A2 positive control HIV-Gag 77-85 peptide.
BCMA-specific CTL generated with heteroclitic BCMA 72-80 (YLMFLLRKI) or BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] [54] [55] [56] [57] [58] [59] [60] [61] [62] CTL generated from three HLA-A2 + individuals demonstrated similar patterns of T-cell activation and costimulatory molecule expression, with the highest upregulation seen on the hBCMA 72-80 CTL (n = 3, *p < 0.05) (Fig. 2c ).
Heteroclitic BCMA 72-80 specific CTL display BCMA antigen-specific immune activities in response to MM cell lines [54] [55] [56] [57] [58] [59] [60] [61] [62] CTL: 22% vs. 14%) and IL-2 production (16% vs. 4%) (Fig. 4a) . In addition, hBCMA 72-80 CTL consistently demonstrated the highest CD107a degranulation, Granzyme B upregulation and IFN-γ/TNF-α Th1 cytokines production in an HLA-A2 restricted manner (Fig. 4b) . The hBCMA 72-80 CTL generated from other HLA-A2 + individuals (n = 3) displayed the same pattern of response and showed significant (*p < 0.05) increases in anti-tumor activities (CD107a degranulation, Granzyme B/Perforin upregulation and IFN-γ/IL-2/TNF-α production) against CD138 + tumor cells from MM patients in an HLA-A2-restricted manner (Fig. 4c) . The robust functional activities by hBCMA 72-80 CTL were aligned with their increased upregulation of T cell activation and co-stimulatory molecule expression (Fig. 2) . Thus, these data provide additional evidence on the great were also within hBCMA 72-80 specific Tetramer + cells (Fig. 5c) . Therefore, these results confirm that anti-MM activities are indeed induced by the BCMA 72-80 peptidespecific CTL, which also display high expression of key Tcell activation markers and co-stimulatory molecules. (Fig. 6a) . Overall, memory CD8 + CTL was gradually developed following each round of heteroclitic BCMA 72-80 peptide stimulation (Fig. 6b) , which was associated with a corresponding decrease in naive T cells (Fig. 6c) . These results therefore demonstrate the induction and gradual expansion of memory CTL upon the stimulation of T cells with heteroclitic BCMA 72-80 peptide. (Fig. 7c) . Finally, the high responders (Donor E, Donor F) to the heteroclitic BCMA 72-80 peptide showed the greatest anti-MM activities and also displayed the highest CM subset frequency as compared to mid-level responder (Donor G) or low-level responder (Donor H). Thus, these results further indicate the distinct enrichment of effector cells with anti-MM activities are predominantly within hBCMA 72-80 specific central memory cell subset. (Fig. 8a) . The checkpoint inhibitor and immune agonist did not induce the anti-MM responses by CD45RO − non-memory cells within the BCMA-CTL. Last, the beneficial effect of anti-LAG3 and anti-OX40 was further investigated within the specific central memory CTL subsets. Anti-LAG3 or anti-OX40 treatment had a greater impact on regulating the functional activity of CM subset compared to EM subset within the hBCMA 72-80 CTL, as evidenced by their higher CD107a degranulation against U266 MM cells (Fig. 8b) . (Fig. 8c) . Therefore, these results support the utility of anti-LAG3 or anti-OX40 to further enhance anti-MM activities of hBCMA 72-80 CTL induced from HLA-A2 + individuals.
Central memory CD8
Discussion
Even in patients with refractory MM relapsing after allotransplantation, long-lasting responses have been achieved with the infusion of donor lymphocytes (DLI) [35, 36] . These early encouraging results of DLI have provided the framework for evaluation of active-specific immunotherapy approaches to treat MM [4, 37, 38] . Cancer targeting vaccines, one such active-specific immunotherapy approach, have demonstrated the ability to induce highly effective CD8 + CTL with anti-tumor activities [39] [40] [41] . The success of vaccination depends on selection of the appropriate patient population, targeting antigens expressed selectively on tumor, and utilizing combination approaches to effectively induce and maintain antigen-specific memory anti-tumor immune responses. We have recently reported on novel immunogenic [11, [42] [43] [44] [45] [46] . In addition, combination studies of peptide stimulation/vaccination with immune modulatory drugs such as lenalidomide or with histone deacetylase 6 inhibitor ACY241 enhanced the peptides-specific CTL activities against tumor cells. Our previous studies demonstrated that combinations of peptide stimulation with either Lenalidomide or ACY241 augmented antigens-specific CD8 + CTL activity associated with upregulation of transcriptional regulators such as T-bet/Eomes and with activation of AKT, which links antigen-specific CTL differentiation to FOXO, mTOR and Wnt/β-catenin signaling pathways [47, 48] . Importantly, these effects were confined primarily to antigen-specific CD45RO + memory CTL, with the most robust increases in IFN-γ and Granzyme B production and CD8 + CTL proliferation in response to tumor cells observed mainly within the specific CM subset. Due to our encouraging preclinical results, the XBP1/ CD138/CS1 multipeptide vaccine has been evaluated, alone and in combination with lenalidomide, in clinical trials to treat patients with smoldering MM (SMM), as well as in combination with anti-PD1 in clinical trials to treat patients with triple-negative breast cancer. In patients with SMM, the multipeptide vaccine was well-tolerated and immunogenic as a monotherapy, evidenced by enhanced frequency of Tetramer + CD8 + CTL with IFN-γ production; moreover, combination with lenalidomide triggered higher mean fold increases in CD8 + T cells with tetramer-positivity and IFN-γ production. Importantly, CD45RO
+ memory CTL specific to the XBP1/CD138/CS1 peptides were induced by the peptide vaccine, and further enhanced in combination with lenalidomide [49, 50] . Although stable disease and responses have been observed in SMM, randomized trials are needed to assess whether time to progression from SMM to active disease can be prolonged by the peptide vaccination.
To expand the MM-specific immunotherapy beyond XBP1/CD138/CS1 antigens, we have recently identified additional tumor-associated antigens on CD138 + tumor cells from newly diagnosed MM patients (N = 616). Here we report on the identification and characterization of a novel immunotherapeutic strategy targeting BCMA, selectively expressed on normal and malignant plasma cells and the target of several current immune treatments in MM. We report on highly immunogenic engineered BCMA-specific nanomers, heteroclitic BCMA 72-80 (YLMFLLRKI), and BCMA [54] [55] [56] [57] [58] [59] [60] [61] [62] (YILWTCLGL), with highly improved HLA-A2 affinity/stability from their native BCMA peptides. These peptides evoke BCMA-specific CTL, increased BCMA-specific Tetramer + cells, enhanced CD107 degranulation, Th1-type cytokines (IFN-γ/IL-2/TNF-α) production, and proliferation to MM cells in an HLA-A2-restricted manner. Most importantly, the increase of BCMA-specific (N = 3) , untreated or treated with anti-OX40, against U266, McCAR or RPMI cells expression of these molecules on XBP1/CD138/CS1-specific CTL generated ex vivo by peptides stimulation [11] . Importantly, the highest induction of co-stimulatory and immune checkpoint molecules was detected on CM subset within hBCMA 72-80 peptide-specific CTL, which is the population that demonstrated the most highly effective poly-functional activities against MM. Importantly, these findings indicated the potential of combination therapy of hBCMA 72-80 peptide with checkpoint inhibitors or immune agonists to enhance the functional anti-MM activities of BCMA-specific CTL. This may be particularly relevant, given the recent concerns when combining pembrolizumab (an antibody targeting PD-1) with immunomodulatory drugs lenalidomide or pomalidomide or with daratumumab (anti-CD38 mAb), where toxicities have curtailed studies [51] [52] [53] . Here, we report on targeting alternative inhibitory receptors and suppressive mechanisms within the MM tumor microenvironment. In particular, LAG3 (CD223) is the third inhibitory receptor to be targeted in the clinic, following CTLA and PD1/PD-L1 [54, 55] and was expressed on BCMA-specific CM CTLs. In parallel, immune agonists, especially the co-stimulatory tumor necrosis factor receptors targeting OX40 (CD134), 41BB (CD137), and GITR (CD357), have received considerable attention for their therapeutic utility in enhancing anti-tumor immune responses; among these, anti-OX40 mAb has recently demonstrated encouraging efficacy in induction of tumor regression by boosting effector T-cell expansion and functional anti-tumor activities in several preclinical studies [56] [57] [58] . Importantly, we used a clinical grade anti-LAG3 and anti-OX40 (provided by Bristol-Myers Squibb; New York, NY) to evaluate changes in the functional activities of heteroclitic BCMA 72-80 specific CTL to MM cells. Our ex vivo studies demonstrated that both anti-LAG3 (checkpoint inhibitor) and anti-OX40 (immune agonist) increased functional activity specifically of memory CTL within the BCMA-CTL against MM cells, without affecting the activity of non-memory CTL. The impact on function of BCMA-CTL generated from multiple HLA-A2
+ individuals' T cells was greater after treatment with anti-OX40 than anti-LAG3, and greater within their specific CM versus EM subset. These studies provide the framework for scientifically informed combination clinical trials of BCMA peptide-specific immunotherapy with the immune agonist or checkpoint inhibitor. In summary, we have identified and validated novel immunogenic HLA-A2-specific native and engineered BCMA peptides, which are capable of inducing antigenspecific CD8
+ CTL with functional anti-tumor activities against MM cells. These results provide the framework for therapeutic application of these highly immunogenic heteroclitic BCMA peptides in MM patients as vaccines and/or as stimuli for expansion of autologous antigen-specific memory CTL. They further support the potential utility of combinations incorporating BCMA peptide vaccine or BCMA-specific adoptive T-cells immunotherapy with anti-OX40 and/or anti-LAG3 to enhance BCMA directed anti-MM responses. Based on the encouraging results presented here, we plan to vaccinate patients with BCMA peptide, treat with BCMA-specific memory T cells expanded ex vivo for adoptive immunotherapy, and then vaccinate again as needed to provide for long term BCMA directed anti-MM immunity.
